Determine your patient’s 24-hour dose

Please refer to the Full Prescribing Information for detailed CDp/LDp dosing guidance.

CDp/LDp INDICATION AND IMPORTANT SAFETY CONSIDERATIONS

INDICATION¹

CDp/LDp is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

SELECT IMPORTANT SAFETY INFORMATION

CDp/LDp is contraindicated in patients who are currently taking a nonselective monoamine oxidase [MAO] inhibitor or have recently (within 2 weeks) taken a nonselective MAO inhibitor.

CDp/LDp may cause:

sudden falling asleep during daily activities. Some patients perceived that they had no warning signs, such as excessive drowsiness. Consider discontinuing CDp/LDp in patients who report significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating).
hallucinations and psychosis. There is an increased risk for hallucinations and psychosis in patients taking CDp/LDp. Patients with a major psychotic disorder should not be treated with CDp/LDp. Hallucinations may be responsive to dose reduction of CDp/LDp or other concomitantly administered medications.
impulse control disorders or compulsive behavior. Consider reducing the dose or discontinuing CDp/LDp if a patient develops such urges.
infusion site reactions and infections. If an infection is suspected at the infusion site, the cannula should be removed from the infusion site. If the cannula is removed for an infection, either a new cannula should be placed at a new infusion site or, in the event of a prolonged interruption, prescribe the patient oral carbidopa/levodopa until they are able to resume CDp/LDp.
withdrawal-emergent hyperpyrexia and confusion. Avoid sudden discontinuation or rapid dose reduction in patients taking CDp/LDp.
dyskinesia or exacerbation of dyskinesia. The occurrence of dyskinesias may require a dosage reduction of CDp/LDp or other medications used to treat PD.

Monitor patients for cardiovascular ischemic events and glaucoma.

The most common adverse reactions (CDp/LDp incidence at least 10% and greater than oral CD/LD incidence) were infusion/catheter site reactions, infusion/catheter site infections, hallucinations, and dyskinesia.

Review CDp/LDp full Prescribing Information for additional information; visit www.rxabbvie.com or contact AbbVie Medical Information at 1-800-633-9110.

References

1. CDp/LDp [package insert]. North Chicago, IL: AbbVie Inc. 2. (carbidopa and levodopa) Tablets [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. 3. (carbidopa, levodopa and entacapone) Tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 4. (carbidopa and levodopa) Sustained-Release Tablets [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. 5. (carbidopa and levodopa) Extended-Release Capsules [package insert]. Bridgewater, NJ: Amneal Specialty, a division of Amneal Pharmaceuticals LLC. 6. Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12)(suppl):1-14. doi:10.1016/S1474-4422(22)00400-8 7. Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson's disease. Mov Disord. 2018;33(6):900-908. doi:10.1002/mds.27340 8. CDp/LDp HCP Pump Instructions for Use. North Chicago, IL: AbbVie Inc. 9. Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12):1099-1109. doi:10.1016/S1474-4422(22)00400-8 10. Data on file. AbbVie Inc. ABVRRTI81269.

SELECT IMPORTANT SAFETY INFORMATION

CDp/LDp is contraindicated in patients who are currently taking a nonselective monoamine oxidase [MAO] inhibitor or have recently (within 2 weeks) taken a nonselective MAO inhibitor.

SELECT IMPORTANT SAFETY INFORMATION

CDp/LDp is contraindicated in patients who are currently taking a nonselective monoamine oxidase [MAO] inhibitor or have recently (within 2 weeks) taken a nonselective MAO inhibitor.

SELECT IMPORTANT SAFETY INFORMATION

CDp/LDp is contraindicated in patients who are currently taking a nonselective monoamine oxidase [MAO] inhibitor or have recently (within 2 weeks) taken a nonselective MAO inhibitor.

SELECT IMPORTANT SAFETY INFORMATION

CDp/LDp is contraindicated in patients who are currently taking a nonselective monoamine oxidase [MAO] inhibitor or have recently (within 2 weeks) taken a nonselective MAO inhibitor.

CDp/LDp INDICATION AND IMPORTANT SAFETY CONSIDERATIONS

INDICATION¹

CDp/LDp is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

SELECT IMPORTANT SAFETY INFORMATION

CDp/LDp is contraindicated in patients who are currently taking a nonselective monoamine oxidase [MAO] inhibitor or have recently (within 2 weeks) taken a nonselective MAO inhibitor.

CDp/LDp may cause:

sudden falling asleep during daily activities. Some patients perceived that they had no warning signs, such as excessive drowsiness. Consider discontinuing CDp/LDp in patients who report significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating).
hallucinations and psychosis. There is an increased risk for hallucinations and psychosis in patients taking CDp/LDp. Patients with a major psychotic disorder should not be treated with CDp/LDp. Hallucinations may be responsive to dose reduction of CDp/LDp or other concomitantly administered medications.
impulse control disorders or compulsive behavior. Consider reducing the dose or discontinuing CDp/LDp if a patient develops such urges.
infusion site reactions and infections. If an infection is suspected at the infusion site, the cannula should be removed from the infusion site. If the cannula is removed for an infection, either a new cannula should be placed at a new infusion site or, in the event of a prolonged interruption, prescribe the patient oral carbidopa/levodopa until they are able to resume CDp/LDp.
withdrawal-emergent hyperpyrexia and confusion. Avoid sudden discontinuation or rapid dose reduction in patients taking CDp/LDp.
dyskinesia or exacerbation of dyskinesia. The occurrence of dyskinesias may require a dosage reduction of CDp/LDp or other medications used to treat PD.

Monitor patients for cardiovascular ischemic events and glaucoma.

Review CDp/LDp full Prescribing Information for additional information; visit www.rxabbvie.com or contact AbbVie Medical Information at 1-800-633-9110.

Determine your patient’s 24-hour dose

CDp/LDp INDICATION AND IMPORTANT SAFETY CONSIDERATIONS

INDICATION1

SELECT IMPORTANT SAFETY INFORMATION ​

SELECT IMPORTANT SAFETY INFORMATION​

SELECT IMPORTANT SAFETY INFORMATION​

SELECT IMPORTANT SAFETY INFORMATION​

SELECT IMPORTANT SAFETY INFORMATION​

CDp/LDp INDICATION AND IMPORTANT SAFETY CONSIDERATIONS

INDICATION1

SELECT IMPORTANT SAFETY INFORMATION ​

INDICATION¹

SELECT IMPORTANT SAFETY INFORMATION

SELECT IMPORTANT SAFETY INFORMATION

SELECT IMPORTANT SAFETY INFORMATION

SELECT IMPORTANT SAFETY INFORMATION

SELECT IMPORTANT SAFETY INFORMATION

INDICATION¹

SELECT IMPORTANT SAFETY INFORMATION